BioCardia Files 8-K: Other Events & Financials

TL;DR

BioCardia dropped an 8-K, check it for the latest company news and financials.

AI Summary

BioCardia, Inc. filed an 8-K on September 19, 2025, reporting other events and financial statements. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.

Why It Matters

This filing indicates BioCardia is providing updates on its corporate activities and financial status to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events but doesn't inherently signal high risk on its own.

Key Numbers

• 001-38999 — SEC File Number (Identifies the company's filing history with the SEC.)
• 23-2753988 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• BioCardia, Inc. (company) — Registrant
• Tiger X Medical, Inc. (company) — Former company name
• September 19, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Sunnyvale, California (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
• $0.001 — 0 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"
• $1.25 — ties"), at a combined offering price of $1.25 per share and Warrant pursuant to secur
• $0.9 million — senting gross proceeds of approximately $0.9 million in the Offering. The expected net proce
• $5.1 million — s to the Company from the Offering were $5.1 million after deducting placement agent fees an

Filing Documents

• bcda20250919_8k.htm (8-K) — 32KB
• ex_862982.htm (EX-4.1) — 107KB
• 0001437749-25-029457.txt ( ) — 292KB
• bcda-20250919.xsd (EX-101.SCH) — 3KB
• bcda-20250919_def.xml (EX-101.DEF) — 11KB
• bcda-20250919_lab.xml (EX-101.LAB) — 15KB
• bcda-20250919_pre.xml (EX-101.PRE) — 11KB
• bcda20250919_8k_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On September 19, 2025, BioCardia, Inc. (the "Company") consummated the sale of 4,800,000 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), and accompanying warrants to purchase up to 4,800,000 shares of Common Stock (the "Warrants" and, together with such shares of Common Stock, the "Securities"), at a combined offering price of $1.25 per share and Warrant pursuant to securities purchase agreements (the "Purchase Agreements") by and between the Company and certain purchasers and pursuant to the Company's Registration Statement (No. 333-290283) on Form S-1, declared effective by the Securities and Exchange Commission on September 18, 2025 (such offering, the "Offering"). Certain of the Company's directors and executive officers purchased an aggregate of 734,400 shares of Common Stock and accompanying Warrants, representing gross proceeds of approximately $0.9 million in the Offering. The expected net proceeds to the Company from the Offering were $5.1 million after deducting placement agent fees and other offering expenses. Each Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other obligations of the parties and termination provisions. In addition, under the Purchase Agreements, the Company agreed to, subject to certain exceptions, not issue, enter into any agreement to issue or announce the issuance or proposed issuance of, any shares of Common Stock (or securities convertible into or exercisable for Common Stock) or, subject to certain exceptions, file any registration statement, including any amendments or supplements thereto (other than the prospectus or a prospectus supplement in connection with the at-the-market offering, and a registration statement on Form S-8), through November 18, 2025. H.C. Wainwright & Co., LLC, the placement agent in the Offering (the "Placement Agent

01 Exhibits

Item 9.01 Exhibits. (d) Exhibits The following exhibits are filed as part of this report: Exhibit No. Description 4.1 Form of Warrant 99.1 (1) Form of Securities Purchase Agreement dated September 18, 2025, by and among BioCardia, Inc. and the signatories thereto. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) (1) Previously filed as Exhibit 10.9 to the registration statement on Form S-1 filed by us on September 16, 2025.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: September 19, 2025

View Full Filing

View this 8-K filing on SEC EDGAR